mp.weixin.qq.com· Best in Class·· 8 hours agoPickScore77
Merck/Kelun-Biotech Report Global Phase 3 TroFuse-005 Endometrial Cancer OS Data for Sacituzumab Tirumotecan: 19.0 vs 12.1 Months
In brief
Merck and Kelun-Biotech reported global phase 3 data for sacituzumab tirumotecan in advanced or recurrent endometrial cancer after immunotherapy, with overall survival of 19.0 months versus 12.1 months. The phase 3 TroFuse-005/ENGOT-en23/GOG-3095 trial (NCT06132958) evaluated the drug in this patient population.
Why it matters
The article gives a direct global phase 3 OS comparison of 19.0 versus 12.1 months, useful for assessing efficacy in post-immunotherapy advanced endometrial cancer.
Source: mp.weixin.qq.com · mp.weixin.qq.com